Last updated: September 7, 2026
Ibudilast, also known as MN-166, remains an investigational U.S. drug candidate owned by MediciNova. Its strongest clinical rationale is in neuroinflammatory and neurodegenerative diseases, particularly progressive multiple sclerosis and amyotrophic lateral sclerosis. The drug is already approved in Japan and China for respiratory and cerebrovascular indications, but it has no U.S. approval, no U.S. Orange Book listing, and no established U.S. exclusivity period.
The commercial outlook is highly dependent on whether MediciNova can demonstrate clinical benefit in ALS, progressive MS, substance-use disorders, or another neuroinflammatory indication. Under a successful ALS or progressive-MS approval, a reasonable U.S. peak-sales range is approximately $200 million to $900 million. The probability-adjusted value is materially lower because the development program remains clinically and financially constrained.
What is ibudilast and how does it work?
Ibudilast is an orally administered small molecule that inhibits several phosphodiesterase enzymes and modulates activated glial cells. The compound has anti-inflammatory, neuroprotective, and potentially anti-addiction effects.
Its proposed mechanisms include:
- Inhibition of PDE-3, PDE-4, PDE-10 and PDE-11 activity.
- Modulation of microglial and astrocyte activation.
- Reduction of pro-inflammatory cytokine signaling.
- Possible attenuation of neuroinflammation associated with CNS injury, demyelination, addiction, and neurodegeneration.
Ibudilast is marketed in Japan under the name Ketas for bronchial asthma and dizziness associated with cerebrovascular disorders. It has also been approved in China for selected respiratory indications. Those approvals do not establish efficacy for ALS, progressive MS, alcohol-use disorder, opioid-use disorder, or methamphetamine-use disorder in the United States.
What is the current development status of ibudilast?
The U.S. development program is led by MediciNova. The principal development areas have been progressive MS, ALS, substance-use disorders, and other CNS conditions.
| Indication |
Development status |
Key evidence or milestone |
Commercial relevance |
| Progressive multiple sclerosis |
Phase 2 completed |
SPRINT-MS reported reduced brain-volume loss versus placebo |
Largest validated neuroinflammatory opportunity, but disability benefit was not established |
| ALS |
Phase 2b/late-stage development activity |
COMBAT-ALS evaluated ibudilast with riluzole and/or edaravone background therapy |
Potential orphan-drug market with high pricing, but efficacy and regulatory risk remain high |
| Alcohol-use disorder |
Phase 2 research |
Studies evaluated effects on craving, reward, and drinking-related behavior |
Large market, but endpoint and reimbursement risk are substantial |
| Methamphetamine-use disorder |
Phase 2 research |
Clinical studies examined reduction of stimulant effects and use |
Significant unmet need, but no validated commercial pathway yet |
| Opioid-use disorder and other CNS disorders |
Earlier-stage or exploratory research |
Neuroinflammatory mechanism has supported investigator-sponsored studies |
Low near-term probability of commercialization |
| Bronchial asthma and cerebrovascular dizziness |
Approved in Japan and China |
Commercialized outside the U.S. |
Existing international revenue base, but mature-product economics |
The most commercially relevant programs are ALS and progressive MS. The SPRINT-MS study provided evidence that ibudilast slowed brain-volume loss in progressive MS, but the study was not designed to establish a definitive reduction in disability progression. That distinction limits the strength of the regulatory case.
What did the progressive-MS clinical program show?
The SPRINT-MS trial was a randomized, placebo-controlled Phase 2 study in progressive multiple sclerosis. Results published in the New England Journal of Medicine showed that ibudilast reduced the rate of brain-volume loss by approximately 48% compared with placebo over the study period.[1]
The main limitation was clinical translation. The study demonstrated an imaging effect rather than a definitive disease-modifying effect on disability. Regulators would likely require evidence that the imaging result predicts meaningful outcomes, or a confirmatory trial using disability progression or another accepted clinical endpoint.
Why is progressive MS still commercially relevant?
Progressive MS has fewer approved treatment options than relapsing MS. The U.S. market includes therapies such as ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS. Ibudilast could occupy a broader progressive-MS position if it showed benefit across nonactive secondary progressive and primary progressive disease.
The opportunity is constrained by:
- Need for a large, long-duration confirmatory trial.
- Competition from established anti-CD20 therapy and other MS drugs.
- Requirement to show more than MRI preservation.
- Potential difficulty obtaining a premium price for an oral therapy without clear disability benefit.
What is the ALS development outlook for ibudilast?
ALS is the highest-value potential indication because it supports orphan-drug pricing and has a concentrated treatment population. Ibudilast has been studied in combination with standard ALS therapy, including riluzole and edaravone.
The COMBAT-ALS program was designed to evaluate whether ibudilast could improve functional outcomes or slow disease progression. ALS development faces severe endpoint risk. A statistically positive result may still require confirmation of survival, respiratory, or functional benefit before broad adoption.
The competitive environment includes:
- Riluzole, including oral and liquid formulations.
- Edaravone, including intravenous and oral suspension formulations.
- Sodium phenylbutyrate/ursodoxicoltaurine, where available and clinically accepted.
- Gene-targeted therapies for genetically defined ALS subgroups.
- Supportive respiratory, nutritional, and mobility care.
Ibudilast would probably be positioned initially as an add-on therapy rather than a replacement for existing ALS treatments. That would reduce the addressable monotherapy market but could support combination use if tolerability and survival data are favorable.
What is the FDA status of ibudilast?
Ibudilast is not approved by the FDA for any indication. It is an investigational new drug candidate in the United States.
The regulatory status can be summarized as follows:
| FDA category |
Status |
| U.S. marketing approval |
None |
| New Drug Application |
No publicly established approval |
| Orange Book listing |
None |
| Biosimilar designation |
Not applicable |
| Small-molecule generic filing risk |
Not applicable before U.S. approval |
| Orphan-drug potential |
Relevant for ALS and potentially progressive MS |
| Fast Track or other expedited status |
Has been associated with development discussions, but designation and current status should be confirmed against FDA records before relying on it for a transaction |
Because there is no approved U.S. product, there is no U.S. Paragraph IV litigation pathway against an ibudilast reference product. A generic manufacturer cannot file an ANDA against an unapproved ibudilast product listed in the Orange Book.
What patents protect ibudilast?
Ibudilast’s original small-molecule protection is likely mature because the drug was developed and approved in Japan decades ago. The original composition-of-matter position is therefore unlikely to provide a meaningful new U.S. patent term for a future launch.
The commercially relevant protection would come from later patents covering:
- Use of ibudilast in ALS.
- Use in progressive MS.
- Use in alcohol-use disorder or stimulant-use disorder.
- Specific dosing regimens.
- Combination therapy with riluzole, edaravone, or other CNS agents.
- Formulations, salts, solid forms, or modified-release delivery.
- Manufacturing processes and pharmaceutical compositions.
Public company disclosures indicate that MediciNova has pursued patent protection around new therapeutic uses and development programs rather than relying solely on the old compound patent.[2][3] The practical value of these patents depends on claim scope, prosecution history, expiration dates, and whether the claims can withstand obviousness and written-description challenges.
How strong is the ibudilast patent estate?
The estate is best characterized as moderate for selected new uses and weak for the underlying molecule.
| Patent layer |
Commercial strength |
| Original composition of matter |
Low, because the compound is an old active ingredient |
| ALS method of use |
Potentially high if claims cover a clinically validated population and dosing regimen |
| Progressive-MS method of use |
Moderate, dependent on confirmatory efficacy |
| Formulation patents |
Moderate if they provide a material pharmacokinetic or tolerability advantage |
| Combination patents |
Moderate to low, depending on whether the combination is clinically unexpected |
| Manufacturing patents |
Potentially useful for supply control, but rarely sufficient to block all generic entry |
Exact patent numbers and expiration dates should not be treated as established without a current, jurisdiction-specific patent-family review. Patent term can differ by country, and U.S. term-adjustment, terminal disclaimers, patent-term extension, and prosecution history may materially affect the effective exclusion period.
What is the Orange Book and generic-entry position?
There is no current U.S. Orange Book listing for ibudilast as an approved drug. The main consequence is timing:
- MediciNova must first obtain FDA approval.
- Any regulatory exclusivity would begin at approval, subject to the granted designation.
- Generic manufacturers could later pursue an ANDA if the product is listed and qualifying patents remain.
- Method-of-use patents may be listed only if they meet FDA listing requirements and correspond to approved labeling.
- Formulation patents may provide stronger practical protection than broad method claims if the approved product relies on a distinctive dosage form.
If ibudilast receives orphan approval for ALS, seven years of U.S. orphan-drug exclusivity could become available for the approved indication. Five years of new chemical entity exclusivity is less likely to be available because ibudilast has been approved outside the United States for many years and may not qualify as a new active ingredient under U.S. law. The final determination would depend on FDA regulatory classification.
Which companies are challenging ibudilast?
No major publicly disclosed U.S. Paragraph IV challenger has an immediate legal position because ibudilast lacks an approved U.S. reference product and Orange Book listing.
The relevant competitive threats are clinical and commercial rather than litigation-based:
- Roche and Genentech, through ocrelizumab, in primary progressive MS.
- Novartis, through siponimod, in active secondary progressive MS.
- Mitsubishi Tanabe Pharma and other suppliers in ALS treatment.
- Amylyx and other developers pursuing ALS therapies, subject to changing regulatory and commercial status.
- Generic manufacturers in Japan and other markets where older ibudilast products face mature-product competition.
What litigation and licensing issues affect ibudilast?
MediciNova obtained rights to develop and commercialize ibudilast from Kyorin-related interests and has disclosed licensing arrangements associated with the compound and its development programs.[2][3]
The main transaction risks are:
- Scope and duration of MediciNova’s territorial rights.
- Royalty obligations on future sales.
- Ownership of new patents created under sponsored or collaborative research.
- Rights to clinical data generated by academic investigators.
- Ability to sublicense regional rights.
- Patent challenges against use or formulation claims.
No major U.S. patent litigation involving ibudilast is established in the cited public-company materials through the available reporting period. The absence of litigation does not indicate a broad blocking position; it primarily reflects that the product has not reached U.S. commercial approval.
What market size could ibudilast reach?
A commercial forecast should separate the approved international base from the unproven U.S. opportunity.
ALS scenario
The U.S. ALS population is commonly estimated at roughly 30,000 patients, with several thousand new diagnoses annually. A commercially successful ibudilast product could target 10,000 to 20,000 treated U.S. patients if it becomes a standard add-on therapy.
| Assumption |
Low case |
Base case |
High case |
| Treated U.S. patients |
5,000 |
12,000 |
20,000 |
| Annual net price |
$25,000 |
$40,000 |
$60,000 |
| U.S. peak sales |
$125 million |
$480 million |
$1.2 billion |
| International sales |
$25 million |
$100 million |
$250 million |
| Timing after approval |
3-5 years |
4-6 years |
5-7 years |
The base case implies approximately $500 million to $600 million in global peak sales. The high case requires clear survival or functional benefit, strong reimbursement, and use with existing ALS medicines.
Progressive-MS scenario
Progressive MS has a larger patient pool than ALS but a more difficult commercial profile. A successful approval could support:
- 10,000 to 30,000 treated patients in the United States.
- Annual net pricing of approximately $15,000 to $30,000.
- U.S. peak sales of roughly $150 million to $900 million.
The upper end would require evidence of disability preservation, broad labeling, and acceptable tolerability. An MRI-only claim would support a substantially smaller market.
Substance-use-disorder scenario
Alcohol-use disorder and stimulant-use disorder represent large populations, but pricing would be lower and access more fragmented. A successful approval could produce a broad prescription market with annual net pricing closer to $3,000 to $10,000 per patient.
A reasonable peak-sales range is $50 million to $300 million for a single substance-use indication. The commercial case would depend on demonstrated reductions in heavy-use days, relapse, or treatment retention rather than only changes in subjective drug effects.
What are the main generic-launch risks?
The generic-launch risk is low before U.S. approval and high after loss of enforceable post-approval protection.
Early launch scenario
If ibudilast receives approval with narrow method-of-use protection and no durable formulation patent, an ANDA filer could target unprotected indications after applicable regulatory exclusivity ends. Generic entry could occur rapidly after patent expiry because the active ingredient is old and manufacturing complexity appears manageable.
Protected launch scenario
A stronger scenario would include:
- Orphan exclusivity for ALS.
- A clinically differentiated formulation.
- Listed formulation or method-of-use patents extending beyond regulatory exclusivity.
- Evidence supporting multiple approved indications.
- Trade-secret control over manufacturing or analytical methods.
Even in this scenario, generic substitution risk would remain higher than for a newly discovered small molecule with a strong composition-of-matter patent.
How does ibudilast compare with competing CNS drugs?
| Attribute |
Ibudilast |
Ocrelizumab |
Siponimod |
Edaravone |
| Modality |
Oral small molecule |
Monoclonal antibody |
Oral small molecule |
Small molecule |
| U.S. approval |
None |
Yes |
Yes |
Yes |
| Primary opportunity |
ALS, progressive MS, substance-use disorders |
Primary progressive and relapsing MS |
Active secondary progressive MS |
ALS |
| Patent strength |
Mature molecule; later-use focus |
Biologic and formulation estate |
Compound and use estate |
Formulation and use protection |
| Generic or biosimilar risk |
Future generic risk |
Future biosimilar risk |
Future generic risk |
Future generic risk |
| Clinical differentiation |
Neuroinflammation and glial modulation |
B-cell depletion |
S1P receptor modulation |
Antioxidant mechanism |
| Key barrier |
Efficacy and regulatory validation |
Safety, infusion, cost |
Patient selection and safety monitoring |
Efficacy, administration, and price |
Key Takeaways
- Ibudilast is approved in Japan and China but remains investigational in the United States.
- The most important development programs are ALS and progressive MS.
- SPRINT-MS produced a strong MRI signal but did not establish definitive disability benefit.
- The original molecule is old, so future commercial protection must rely on new-use, formulation, combination, and manufacturing patents.
- Ibudilast has no U.S. Orange Book listing and no current Paragraph IV litigation exposure.
- A successful ALS launch could support approximately $200 million to $900 million in global peak sales, with substantial variation based on efficacy and pricing.
- Progressive MS has a larger theoretical market but requires stronger clinical evidence than an imaging endpoint alone.
- The principal risks are clinical validation, limited corporate resources, regulatory exclusivity, and rapid generic entry after enforceable protection expires.
FAQs
Could ibudilast receive orphan-drug exclusivity for ALS?
Yes. ALS is an orphan disease in the United States, and an ibudilast product could qualify for seven years of orphan-drug exclusivity if FDA grants the designation and approves the drug for that indication. Orphan exclusivity would apply to the approved use, not necessarily to every use of ibudilast.
Is ibudilast a biosimilar risk or a generic-drug risk?
Ibudilast is a small molecule, so the relevant future threat is generic competition through the ANDA pathway, not biosimilar competition through the biologics pathway.
Can the old ibudilast molecule receive new U.S. patent protection?
The old composition itself is unlikely to support a new patent term. New patents may protect a specific therapeutic use, patient population, dosing regimen, formulation, combination, or manufacturing process if statutory patentability requirements are met.
What would most improve ibudilast’s valuation?
A controlled trial showing a clinically meaningful reduction in ALS functional decline, respiratory deterioration, or mortality would have the greatest impact. In progressive MS, a confirmed reduction in disability progression would be more valuable than another imaging-only result.
Does existing approval in Japan reduce U.S. development risk?
It reduces some manufacturing and general tolerability risk because the compound has prior human exposure. It does not remove the U.S. efficacy, clinical-endpoint, regulatory-exclusivity, reimbursement, or patent risks associated with a new indication.
References
1.ومین, R. M., et al. (2018). Safety and efficacy of ibudilast in progressive multiple sclerosis. New England Journal of Medicine, 379(9), 846-855.
-
MediciNova, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
MediciNova, Inc. (2024). Corporate reports and clinical development updates for MN-166 (ibudilast). MediciNova, Inc.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Orphan-drug designation and exclusivity provisions. FDA.
